<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03993171</url>
  </required_header>
  <id_info>
    <org_study_id>CNMAu8.207</org_study_id>
    <nct_id>NCT03993171</nct_id>
  </id_info>
  <brief_title>31P-MRS Imaging to Assess the Effects of CNM-Au8 on Impaired Neuronal Redox State in Multiple Sclerosis (REPAIR-MS)</brief_title>
  <official_title>A Phase 2, Open Label, Sequential Group, Investigator Blinded Study of Magnetic Resonance Spectroscopy (31P-MRS) to Assess the Effects of CNM-Au8 for the Bioenergetic Improvement of Impaired Neuronal Redox State in Multiple Sclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Clene Nanomedicine</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Texas Southwestern Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Clene Nanomedicine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      REPAIR-MS is a single-center open label, sequential group, investigator and patient blinded
      study to assess the CNS metabolic effects, safety, pharmacokinetics, and pharmacodynamics of
      CNM-Au8 in patients who have been diagnosed with Multiple Sclerosis (MS) within fifteen (15)
      years of Screening. The primary endpoint is the ratio of the oxidized to reduced form of
      nicotinamide adenine dinucleotide (NAD+:NADH) measured non-invasively by 31phosphorous
      magnetic resonance spectroscopy (31P-MRS).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a single-center open label, sequential group, investigator blinded study of the CNS
      metabolic effects, safety, pharmacokinetics, and pharmacodynamics of CNM-Au8 in patients who
      have been diagnosed with Multiple Sclerosis (MS) within fifteen years of Screening. The
      Sponsor will select a starting treatment dose of CNM-Au8 for the initial treatment.
      Investigators and patients will be blinded to each cohort's study dose. Upon completion of
      the first treatment cohort, the Sponsor will select a single dose or two different doses for
      the subsequent second cohort from a pre-specified dosing selection plan based on the
      evaluation of the 31P-Magnetic Resonance Spectroscopy (31P-MRS) changes versus baseline in
      the first cohort. Up to a total of two treatment cohorts may be studied (n=12
      patients/cohort, total n=24 patients). All patients will receive daily oral treatment over
      twelve consecutive weeks during each cohort's Treatment Period.

      There will be three study periods per treatment cohort:

      A four-week screening period (Screening Period); A twelve-week treatment period (Treatment
      Period); A six-week follow-up period (End-of-Study Assessment). The primary study outcome,
      CNS metabolic changes, will be assessed based upon each patient's Week 12 study visit versus
      the pre-treatment baseline. The primary endpoint is the brain metabolic effects of treatment
      with CNM-Au8 as assessed by an improvement of 31P-MRS assessment of Brain Tissue Cellular
      Redox Potential defined by the measured tissue ratio of NAD+:NADH concentrations following 12
      weeks of once daily treatment.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">January 2020</start_date>
  <completion_date type="Anticipated">November 2020</completion_date>
  <primary_completion_date type="Anticipated">October 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Open Label, Investigator Blinded, Sequential Cohort (max of 2 cohorts amongst the possible 4 interventions)</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>Research participants and site personnel are not masked to study drug, but will be blinded to study dose for each cohort (single-blinded).</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change in 31P-MRS Redox Ratio (NAD+/NADH)</measure>
    <time_frame>At 12 Weeks</time_frame>
    <description>Mean change in average NAD+/NADH measured brain Redox Ratio by treatment group</description>
  </primary_outcome>
  <other_outcome>
    <measure>Mean Change in 31P-MRS Bioenergetic Metabolite CNS Tissue Concentration of NAD+</measure>
    <time_frame>At 12 Weeks</time_frame>
    <description>Mean change in average CNS concentration of NAD+ [mmol/kg] by treatment group</description>
  </other_outcome>
  <other_outcome>
    <measure>Mean Change in 31P-MRS Bioenergetic Metabolite CNS Tissue Concentration of NADH</measure>
    <time_frame>At 12 Weeks</time_frame>
    <description>Mean change in average CNS concentration of NADH [mmol/kg] by treatment group</description>
  </other_outcome>
  <other_outcome>
    <measure>Mean Change in 31P-MRS Bioenergetic Metabolite CNS Tissue Concentration of Pooled NAD+/NADH</measure>
    <time_frame>At 12 Weeks</time_frame>
    <description>Mean change in average CNS concentration of pooled NAD+/NADH [mmol/kg] by treatment group</description>
  </other_outcome>
  <other_outcome>
    <measure>Mean Change in 31P-MRS Bioenergetic Metabolite CNS Tissue Concentration of Phosphocreatine (PCr)</measure>
    <time_frame>At 12 Weeks</time_frame>
    <description>Mean change in average CNS concentration of PCr [mmol/kg] by treatment group</description>
  </other_outcome>
  <other_outcome>
    <measure>Mean Change in 31P-MRS Bioenergetic Metabolite CNS Tissue Concentration of Intracellular Inorganic Phosphate (Pi(in))</measure>
    <time_frame>At 12 Weeks</time_frame>
    <description>Mean change in average CNS concentration of Pi(in) [mmol/kg] by treatment group</description>
  </other_outcome>
  <other_outcome>
    <measure>Mean Change in 31P-MRS Bioenergetic Metabolite CNS Tissue Concentration of Extracellular Inorganic Phosphate (Pi(ex))</measure>
    <time_frame>At 12 Weeks</time_frame>
    <description>Mean change in average CNS concentration of Pi(ex) [mmol/kg] by treatment group</description>
  </other_outcome>
  <other_outcome>
    <measure>Mean Change in 31P-MRS Bioenergetic Metabolite CNS Tissue Concentration of Uridine Diphosphate Glucose (UDPG)</measure>
    <time_frame>At 12 Weeks</time_frame>
    <description>Mean change in average CNS concentration of UDPG [mmol/kg] by treatment group</description>
  </other_outcome>
  <other_outcome>
    <measure>Mean Change in 31P-MRS Membrane Component Tissue Concentration of Phosphoethanolamine (PE)</measure>
    <time_frame>At 12 Weeks</time_frame>
    <description>Mean change in average CNS concentration of PE [mmol/kg] by treatment group</description>
  </other_outcome>
  <other_outcome>
    <measure>Mean Change in 31P-MRS Membrane Component CNS Tissue Concentration of Phosphocholine (PC)</measure>
    <time_frame>At 12 Weeks</time_frame>
    <description>Mean change in average CNS concentration of PC [mmol/kg] by treatment group</description>
  </other_outcome>
  <other_outcome>
    <measure>Mean Change in 31P-MRS Membrane Component CNS Tissue Concentration of glycerophosphoethanolamine (GPE)</measure>
    <time_frame>At 12 Weeks</time_frame>
    <description>Mean change in average CNS concentration of GPE [mmol/kg] by treatment group</description>
  </other_outcome>
  <other_outcome>
    <measure>Mean Change in 31P-MRS Membrane Component CNS Tissue Concentration of Glycerophosphocholine (GPC)</measure>
    <time_frame>At 12 Weeks</time_frame>
    <description>Mean change in average CNS concentration of GPC [mmol/kg] by treatment group</description>
  </other_outcome>
  <other_outcome>
    <measure>Mean Change in Multiple Sclerosis Functional Composite (MSFC)</measure>
    <time_frame>At 12 Weeks</time_frame>
    <description>Mean change in Multiple Sclerosis Functional Composite (MSFC) by treatment group from Baseline to Week 12.
The MSFC is a composite score generated by comparing the average results from three assessment on an individual basis to the population mean at the Baseline Visit. The MSFC includes the timed 25 foot walk test, the 9-hole peg test, and the paced auditory serial additional test.</description>
  </other_outcome>
  <other_outcome>
    <measure>Mean Change in Symbol Digit Modality Test (SDMT)</measure>
    <time_frame>At 12 Weeks</time_frame>
    <description>Mean change in Symbol Digit Modality Test (SDMT) by treatment group from Baseline to Week 12</description>
  </other_outcome>
  <other_outcome>
    <measure>Mean Change in Optical Coherence Tomography (OCT) Retinal Layers</measure>
    <time_frame>At 12 Weeks</time_frame>
    <description>Mean change in Optical Coherence Tomography (OCT) retinal layers by macular scan of Ganglion Cell + inner plexiform layer (GCIPL), Outer nuclear layer (ONL) and Inner nuclear layer (INL)</description>
  </other_outcome>
  <other_outcome>
    <measure>Mean Change in Optical Coherence Tomography (OCT) Retinal Nerve Fiber Layer</measure>
    <time_frame>At 12 Weeks</time_frame>
    <description>Mean change in Retinal Nerve Fiber Layer by Peripapillary Scan (pRNFL)</description>
  </other_outcome>
  <other_outcome>
    <measure>Mean Change in Myelin Volume Fraction (MVF)</measure>
    <time_frame>At 12 Weeks</time_frame>
    <description>Mean change in Myelin volume fraction (MVF) in baseline lesions and in normal appearing white matter (NAWM).</description>
  </other_outcome>
  <other_outcome>
    <measure>Mean Change in Restricted Volume Fraction (F_R)</measure>
    <time_frame>At 12 Weeks</time_frame>
    <description>Mean Change in Restricted Volume Fraction (F_R) in baseline lesions and in normal appearing white matter (NAWM).</description>
  </other_outcome>
  <other_outcome>
    <measure>Mean Change in CSF Volume Fraction (F_CSF)</measure>
    <time_frame>At 12 Weeks</time_frame>
    <description>Mean change in CSF Volume Fraction (F_CSF) between Baseline and Week 12 MRI</description>
  </other_outcome>
  <other_outcome>
    <measure>Mean Change in Axonal Volume Fraction (AVF)</measure>
    <time_frame>At 12 Weeks</time_frame>
    <description>Mean Change in Axonal Volume Fraction (AVF) in baseline lesions and in normal appearing white matter (NAWM).</description>
  </other_outcome>
  <other_outcome>
    <measure>Mean Change in G-Ratio</measure>
    <time_frame>At 12 Weeks</time_frame>
    <description>Mean change in g-ratio in baseline lesion and in normal appearing white matter (NAWM) represented as an aggregate measure calculated on a per-voxel basis</description>
  </other_outcome>
  <other_outcome>
    <measure>Mean Change in G-Ration Susceptibility</measure>
    <time_frame>At 12 Weeks</time_frame>
    <description>Mean change in the g-ratio susceptibility (ppm) in baseline lesion and in normal appearing white matter (NAWM).</description>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Relapsing Remitting Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>7.5mg CNM-Au8</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>7.5mg suspension of clean-surfaced, faceted, gold nanocrystals in 120ml of sodium bicarbonate buffered water</description>
  </arm_group>
  <arm_group>
    <arm_group_label>15mg CNM-Au8</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>15mg suspension of clean-surfaced, faceted, gold nanocrystals in 120ml of sodium bicarbonate buffered water</description>
  </arm_group>
  <arm_group>
    <arm_group_label>30mg CNM-Au8</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>30mg suspension of clean-surfaced, faceted, gold nanocrystals in 120ml of sodium bicarbonate buffered water</description>
  </arm_group>
  <arm_group>
    <arm_group_label>60mg CNM-Au8</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>60mg suspension of clean-surfaced, faceted, gold nanocrystals in 120ml of sodium bicarbonate buffered water</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gold nanocrystals</intervention_name>
    <description>CNM-Au8 is a dark red/purple-colored liquid formulation consisting of a stable suspension of faceted clean surfaced elemental gold nanocrystals in buffered deionized water with a concentration of up to 0.5 mg/mL of gold. The formulation is buffered by sodium bicarbonate present at a concentration of 0.546 mg/mL. There are no other excipients. The drug product is formulated to be taken orally and will be provided in single dose HDPE containers. The study doses vary by the concentration of gold nanocrystals per milliliter in a volume of 60 mL.</description>
    <arm_group_label>15mg CNM-Au8</arm_group_label>
    <arm_group_label>30mg CNM-Au8</arm_group_label>
    <arm_group_label>60mg CNM-Au8</arm_group_label>
    <arm_group_label>7.5mg CNM-Au8</arm_group_label>
    <other_name>CNM-Au8</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. At least 18 years of age and up to 55 years (inclusive) of age at Baseline.

          2. Clinical diagnosis of Multiple Sclerosis (MS) who have had Relapsing MS (RMS) no
             longer than 15 years from diagnosis.

          3. Stable treatment with natalizumab for at least the prior six (6) months.

          4. Stable disease activity over the prior six (6) months.

          5. All hematological parameters and biochemical parameters deemed stable or transient in
             nature.

          6. Able to understand and give written informed consent.

        Exclusion Criteria:

          1. Patients with a clinical relapse requiring systemic steroid treatment within the prior
             six (6) months.

          2. Patients treated with any other MS therapy other than natalizumab; or treated with
             clemastine fumarate.

          3. Patients with a history of significant other major medical condition that may
             interfere with the conduct of the study or interpretation of the study results.

          4. Patients who may have difficulty complying with the protocol and/or study procedures.

          5. Patient with clinically significant abnormalities in hematology, blood chemistry, ECG,
             or physical examination not resolved by the Baseline visit which according to
             Investigator can interfere with study participation.

          6. Patients with clinically significant hepatic or renal dysfunction or clinical
             laboratory findings that would limit the interpretability of change in liver or kidney
             function, or those with low platelet counts (&lt; 150 x 109 per liter) or eosinophilia
             (absolute eosinophil count of â‰¥500 eosinophils per microliter).

          7. Patients with a prior history of, or positive serological assay for the presence of
             HIV infection, or laboratory evidence of active or chronic infection with hepatitis C
             (HCV) or hepatitis B (HBV).

          8. Patients participating in any other investigational drug trial or using an
             investigational drug (within 12 weeks prior to screening and thereafter)

          9. Positive screen for drugs of abuse or known alcohol abuse.

         10. Females who are pregnant, have a positive pregnancy test, are nursing, or who plan to
             get pregnant during the course of this clinical trial or within 6 months of the end of
             this trial.

         11. Women of child-bearing potential, or men, who are unwilling or unable to use accepted
             methods of birth control during the study and for 6 months following completion of
             study participation.

         12. Patients with implanted metal objects in their body that may be affected by an MRI
             procedure.

         13. Patients who are claustrophobic or otherwise unlikely to be able to complete the MRI
             scanning procedures.

         14. Patients with a history of gold allergy.

         15. Patient is considered a suicide risk in the opinion of the Investigator, has
             previously made a suicide attempt, or is currently demonstrating active suicidal
             ideation.

         16. Any active ophthalmological cause for retinal damage other than MS or based on the
             Investigator's judgment any other ophthalmic diseases that would confound the study
             results or optical coherence tomography assessment.

         17. PRN use of stimulant medications including: amphetamine, dextroamphetamine,
             lisdexamfetamine, methylphenidate, or modafinil.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Benjamin Greenberg, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Texas Southwestern Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Austin Rynders, RN</last_name>
    <phone>(801) 676-9695</phone>
    <email>info@clene.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Michael Hotchkin</last_name>
    <phone>(801) 676-9695</phone>
    <email>info@clene.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Texas Southwestern</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Benjamin Greenberg, MD</last_name>
      <phone>214-645-0563</phone>
      <email>Benjamin.Greenberg@UTSouthwestern.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>May 31, 2019</study_first_submitted>
  <study_first_submitted_qc>June 18, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 20, 2019</study_first_posted>
  <last_update_submitted>January 13, 2020</last_update_submitted>
  <last_update_submitted_qc>January 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>neurodegeneration</keyword>
  <keyword>gold</keyword>
  <keyword>nanoparticle</keyword>
  <keyword>NAD+</keyword>
  <keyword>redox</keyword>
  <keyword>31P-MRS</keyword>
  <keyword>multiple sclerosis</keyword>
  <keyword>magnetic resonance spectroscopy</keyword>
  <keyword>nanocrystal</keyword>
  <keyword>NADH</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis, Relapsing-Remitting</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

